What patients tell us
“My doctor ordered a blood lead level and a blood mercury and they came back fine. But I have neurological symptoms no one can explain, my labs show patterns no one's connecting, and I've had a lot of dental work and a lot of imaging over the years. Is something else going on?”
Why this page covers four metals together
This page focuses on four heavy metals that recur most often in iHeal's clinical practice: lead, mercury, gadolinium, and arsenic. Each has a distinct primary exposure pathway and a distinct clinical fingerprint, but they share enough mechanism — mitochondrial toxicity, immune dysregulation, endocrine disruption — that evaluating them together makes clinical sense. Most patients with meaningful accumulated metal burden have exposure from more than one of these sources.
Lead: persistent legacy exposure
Lead exposure declined substantially after leaded gasoline was phased out and lead paint was banned in 1978, but legacy exposure persists in older housing, water systems, and certain occupational and recreational sources. The diagnostic reality is that the blood compartment reflects recent exposure, while the body's total burden lives in tissue — bone, in particular, stores lead and continues to release it back into circulation over time. A patient with a normal blood lead level may have substantial tissue burden affecting cardiovascular, cognitive, and renal function.
Clinical patterns consistent with lead burden include resistant hypertension, peripheral neuropathy, cognitive decline disproportionate to age, renal dysfunction without other clear cause, and gout. The exposure history is the diagnostic anchor: pre-1978 housing, occupational exposure, recreational exposure, and historical childhood exposure.
Mercury: dental and dietary
Mercury exposure has two primary contemporary pathways: dental amalgam (approximately 50% elemental mercury by weight, off-gassing slowly over the life of the filling) and dietary mercury from large predatory fish. Like lead, mercury has tissue compartmentalization that limits the diagnostic utility of unprovoked blood testing alone. Clinical patterns include cognitive symptoms, mood symptoms, peripheral neuropathy, autoimmune patterns, thyroid dysfunction, and gastrointestinal symptoms.
Gadolinium: the medical exposure metal
Gadolinium-based contrast agents are used in MRI imaging. Research has documented that gadolinium deposition occurs in brain, bone, and other tissues even in patients with normal renal function, accumulating with repeated administrations. The FDA added warnings about gadolinium retention to contrast agent labels in 2018. A subset of patients report a constellation of symptoms — severe persistent headaches, cognitive symptoms, peripheral pain and burning sensations, dermatologic and musculoskeletal findings — that emerged or worsened after gadolinium exposure.
Arsenic: environmental exposure
Arsenic exposure occurs through contaminated drinking water (particularly private wells in regions with naturally occurring arsenic), through food (rice and rice products), and through certain occupational sources. Chronic arsenic exposure produces peripheral neuropathy, cardiovascular effects, skin findings, increased cancer risk, diabetes, and immune effects.
How iHeal evaluates heavy metal exposure
The evaluation strategy is built around the reality that the blood compartment reflects recent exposure while clinically significant burden lives in tissue. iHeal uses provoked urinary testing — administering a chelating agent and measuring the resulting urinary excretion — as a core diagnostic tool when the clinical picture suggests meaningful accumulated metal exposure. A chelating agent such as DMSA, DMPS, or EDTA mobilizes metals from their tissue stores into circulation, where the kidneys excrete them. The urinary excretion under provocation reflects the mobilizable body burden in a way that baseline urinary testing cannot capture.
Provoked testing requires clinical correlation, like any diagnostic study. Results are interpreted in the context of exposure history, symptom pattern, and the broader 5M evaluation. The choice of chelating agent depends on the metal in question, the patient's clinical status, and the goals of the evaluation.
How treatment proceeds when warranted
Treatment of heavy metal accumulation is gradual and deliberate. The clinical approach prioritizes preparing the patient first — supporting mast cell function, mitochondrial capacity, nutrient status, gut barrier integrity, and detoxification pathway function — before progressive chelation. Mineral repletion during chelation is essential, and treatment is monitored both biochemically and clinically.
Pro Tip · From Dr. Everett
The evaluation strategy is built around the reality that the blood compartment reflects recent exposure while clinically significant burden lives in tissue. iHeal uses provoked urinary testing — administering a chelating agent and measuring the resulting urinary excretion — as a core diagnostic tool when the clinical picture suggests meaningful accumulated metal exposure. A chelating agent such as DMSA, DMPS, or EDTA mobilizes metals from their tissue stores into circulation, where the kidneys excrete them. The urinary excretion under provocation reflects the mobilizable body burden in a way that baseline urinary testing cannot capture.
Sources & Further Reading
- ATSDR Toxicological Profiles: Lead, Mercury, Arsenic atsdr.cdc.gov/toxprofiles
- CDC: Lead Exposure and Toxicity cdc.gov/nceh/lead
- FDA: Gadolinium-Based Contrast Agents Safety Information fda.gov/drugs/drug-safety-and-availability
- EPA: Arsenic in Drinking Water epa.gov/dwreginfo/drinking-water-regulations
- Peer-Reviewed: Heavy metal toxicology and chronic disease — PubMed-indexed; references in Environmental Health Perspectives
Concerned this applies to you?
A consultation is where we figure out whether heavy metals is actually contributing to your symptoms — and what to do about it.